Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > “Second mouse gets the cheese “

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 11, 2024 11:51am

70 Views

Post# 36306683

RE:RE:RE:RE:RE:“Second mouse gets the cheese “

The irony of CGON's pursuit of bladder cancer is that in around 2007 Brad Thompson had the opportunity of addressing the bladder cancer market with pelareorep but chose not to do so. This speaks volumes on Thompson's and his BOD lack of insightfulness.The rest is history.

<< Previous

Bullboard Posts

Next >>

Nvidia reports record revenue in Q3